Paper Review Records
All Paper Review Records
14 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
140
days
Tucatinib, trastuzumab, and capecitabine as second- or third-line therapy after trastuzumab deruxtecan in HER2-positive metastatic breast cancer: A multicenter retrospective study in France
Authors
JeanSebastien Frenel; Alexandre de Nonnevile; Catherine Guerin-Charbonnel; Jean Zeghondy; Laurent Mathiot; Audrey Mailliez; François Poumeaud; Nicolas Isambert; Monica Arnedos; Fanny Le Du; Loick Galland; Rayan Kabirian; Severine Guiu; Laura Poestch; Elise Deluche; François Cherifi; Florence Dalenc; Elsa Volant; Barbara Pistilli; Tevy San; Thomas Bachelot; Anne Patsouris; François Bocquet; Caroline Bailleux; Delphine Loirat; Louis LarrouquereShow moreShow less
Affiliations
Medical Oncology, Institut de Cancérologie de l’Ouest, Saint-Herblain, France; Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France; Oncology Data Factory And Analytics, Institut de Cancérologie de l’Ouest, Saint-Herblain, France; Medical Oncology, Gustave Roussy, Villejuif, France; Medical Oncology, Centre Oscar Lambret, Lille, France; Medical Oncology, Oncopole, IUCT, Claudius Regaud, Toulouse, France; Medical Oncology, CHU Poitiers, Poitiers, France; Medical Oncology, Centre Bergonié, Bordeaux, France; Medical Oncology, Centre Eugène Marquis, Rennes, France; Medical Oncology, Centre Georges-François Leclerc, Saint-Herblain, France; Medical Oncology, Institut Curie, Paris, France; Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France; Medical Oncology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Medical Oncology, CHU de Limoges, Limoges, France; Medical Oncology, Centre François Baclesse, Caen, France; Medical Oncology, CORT 37, Chambray-lès-Tours, France; Medical Oncology, Centre Léon Bérard, Lyon, France; Medical Oncology, Institut de Cancérologie de l’Ouest, Angers, France; Data Factory and Analytics, Institut de Cancérologie de l’Ouest, Saint-Herblain, France; Medical Oncology, Centre Antoine Lacassagne, Nice, FranceShow moreShow less
145
days
Analysis of outcomes of nab-paclitaxel compared to other taxanes in early breast cancer: A study revealing the critical role of calendar-time bias in real-world drug comparisons
Authors
Jingjing Xiao; Meiling Huang; Changjiao Yan; Zhe Wang; Ting WangShow moreShow less
Affiliations
Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, ChinaShow moreShow less
282
days
Performance of large language models in ambiguous treatment scenarios of early breast cancer
Authors
Anton Oseledchyk; Walter Paul Weber; Benjamin KasendaShow moreShow less
Affiliations
Medical Oncology, University Hospital Basel, Basel, Switzerland; Breast Cancer Center, University Hospital Basel, Basel, SwitzerlandShow moreShow less
74
days
Transcriptomic signatures of mind-body transformations therapy in breast cancer: Downregulation of the interferon signaling pathway
Authors
Stefania Cocco; Mauro Cozzolino; Michela Piezzo; Giovanna Celia; Daniela Barberio; Valentina Abate; Alessandra Calabrese; Claudia Von Arx; Rossana Di Rienzo; Susan Costantini; Alfredo Budillon; Michelino De LaurentiisShow moreShow less
Affiliations
Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy; Department of Human, Philosophical and Educational Sciences, University of Salerno, Salerno, Italy; Department of Theoretical and Applied Sciences, Ecampus University, Novedrate, Italy; Departmental Simple Unit of Psycho-oncology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy; Experimental Pharmacology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy; Scientific Directorate, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, ItalyShow moreShow less
133
days
Cost-effectiveness of abbreviated breast MRI and contrast-enhanced mammography for women with extremely dense breasts in a national breast cancer screening program: a micro-simulation study
Authors
Mengmeng Li; Marcel J.W. Greuter; Keris Poelhekken; Monique D. Dorrius; Karin M. Vermeulen; Antoinette D.I. van Asselt; Geertruida H. de BockShow moreShow less
Affiliations
Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Department of Radiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Department of Health Science, University Medical Center Groningen, University of Groningen, Groningen, the NetherlandsShow moreShow less
123
days
Revisiting HER2-negative breast cancer in the era of HER2-low and HER2-ultralow expression: Assessment of interobserver variability
Authors
Xiao Huang; Sarah Anderson; Valeria Dal Zotto; Shuko Harada; Andrea G Kahn; Meiling Zhou; Kui Zhang; Kanako Okamoto; Shi WeiShow moreShow less
Affiliations
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Mathematical Sciences, Michigan Technological University, Houghton, MI, USA; Department of Statistics, Grand Valley State University, Allendale, MI, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USAShow moreShow less
FAQ
How long does BREAST take to review a manuscript?
As of 2026-11-19, CrushSCI has 14 complete review records for BREAST. The fastest paper went from submission to acceptance in 55 days (End-of-life care values and treatment preferences among Japanese breast cancer patients and families: A dyadic cross-sectional study, received 2026-06-16, accepted 2026-08-10); the slowest took 307 days. The average is 144.1 days and the median is 136.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
